Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | GALR3 | O60755 | 2/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.50 |
| ▸ | MTOR | P42345 | 2/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2880271 | 1.00 | MAOB (0.61) | MAOBMAOAERBB2LMNAHTT | |
| SCHEMBL2882489 | 0.89 | HTT (0.59) | LMNAHTTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL2882487 | 0.89 | HTT (0.59) | LMNAHTTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL2882955 | 0.87 | HPGD (0.54) | MAOBMAOAEGFRPTPN1HPGD | |
| SCHEMBL2882953 | 0.87 | HPGD (0.54) | MAOBMAOAEGFRPTPN1HPGD | |
| SCHEMBL12975471 | 0.82 | CISD1 (0.56) | MAOBMAOAHTTHPGDRAB9A | |
| SCHEMBL2877560 | 0.82 | CISD1 (0.56) | MAOBMAOAHTTHPGDRAB9A | |
| SCHEMBL2877564 | 0.82 | CISD1 (0.56) | MAOBMAOAHTTHPGDRAB9A | |
| SCHEMBL2884910 | 0.80 | LMNA (0.67) | ERBB2LMNAHTTSMN1; SMN2EGFR | |
| SCHEMBL2884674 | 0.79 | PIM1 (0.56) | MAOBMAOAPTPN1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | claimed |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | MERCK SERONO SA (CH) | 2009-02-12 | — | — | US | claimed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | claimed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | claimed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | LABORATOIRES SERONO S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2006-06-08 | — | — | US | disclosed |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) | 2005-10-06 | — | — | US | disclosed |
| EP-1549644-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004007491-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306069-A1 | AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES | ZAP70, BRCA1, ZYX | MAOB 1382/4885MAOA 2983/4885ERBB2 412/4885 |
| US-20090042773-A1 | P13 kinase gamma inhibitors for the treatment of anaemia | PDPK1, PRKD3, PRKD1 | MAOB 3943/4885MAOA 4354/4885ERBB2 617/4885 |
| US-20050222225-A1 | Use of compounds for increasing spermatozoa motility | CATSPER1, PI4KB, MAN2B2 | MAOB 2428/4885MAOA 3151/4885ERBB2 4868/4885 |
| US-20080306057-A1 | P13K Inhibitors for the Treatment of Endometriosis | PDPK1, PIK3R4, MAP3K3 | MAOB 3973/4885MAOA 4012/4885ERBB2 1593/4885 |
| US-20060122176-A1 | Azolidinone-vinyl fused-benzene derivatives | BRCA1, ZAP70, F13B | MAOB 1601/4885MAOA 3069/4885ERBB2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.